{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:33:21Z","timestamp":1782876801815,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.01.062","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T10:15:27Z","timestamp":1486116927000},"page":"1254-1258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2\u201349years"],"prefix":"10.1016","volume":"35","author":[{"given":"Roger","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Aukes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Caspard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.01.062_b0005","unstructured":"FluMist\u00ae Quadrivalent (Influenza Vaccine Live, Intranasal): US prescribing information. Gaithersburg, MD: MedImmune; 2016."},{"key":"10.1016\/j.vaccine.2017.01.062_b0010","unstructured":"US Food and Drug Administration. February 29, 2012 Approval Letter\u2013FluMist\u00ae Quadrivalent; 2012. Available from: <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm294293.htm> [last accessed: 31 August 2016]."},{"key":"10.1016\/j.vaccine.2017.01.062_b0015","unstructured":"US Food and Drug Administration. June 17, 2003 Approval Letter\u2013Influenza Virus Vaccine Live, Intranasal; 2003. Available from: <http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm123753.htm> [last accessed: 31 August 2016]."},{"key":"10.1016\/j.vaccine.2017.01.062_b0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1750-2659.2011.00243.x","article-title":"An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2\u201317 years","volume":"5","author":"Ambrose","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2017.01.062_b0025","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.inf.0000237829.66310.85","article-title":"Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections","volume":"25","author":"Ashkenazi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.062_b0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.01.062_b0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0022-3476(00)70097-7","article-title":"Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A\/Sydney) not contained in the vaccine","volume":"136","author":"Belshe","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2017.01.062_b0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/01.inf.0000237797.14283.cf","article-title":"Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma","volume":"25","author":"Fleming","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.062_b0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial","volume":"282","author":"Nichol","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.01.062_b0050","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.vaccine.2012.02.039","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.062_b0055","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2013.01.055","article-title":"A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24\u201359 months of age","volume":"31","author":"Toback","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.062_b0060","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2012.02.080","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18\u201349 years of age","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.062_b0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0b013e31825687b0","article-title":"Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.01.062_b0070","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1016\/j.vaccine.2011.09.109","article-title":"A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults","volume":"29","author":"Block","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.01.062_b0075","first-page":"S49","article-title":"Statistical assessment of the association between vaccination and rare adverse events post-licensure","volume":"20","author":"Andrews","year":"2002","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.01.062_b0080","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2017.04.061","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17301287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:55:25Z","timestamp":1536065725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17301287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17301287"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.062","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2017.04.061","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2\u201349years","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}